Efficacy of a single dose switch from aflibercept to ranibizumab in the treatment of neovascular age-related macular degeneration. [PDF]
PLoS OneIby J +6 more
europepmc +1 more source
Expanding horizons of intravitreal anti-vascular endothelial growth factor therapy in retinal diseases. [PDF]
Indian J OphthalmolSingh S, Kala U, Bamel A, Agarwal M.
europepmc +1 more source
Visual Outcomes Following Infectious Endophthalmitis from Intravitreal Injections of Biologic Drugs: An Intelligent Research in Sight Registry Retrospective Analysis. [PDF]
Ophthalmol TherZhang R, Tunon-Robinson I, Nguyen AK.
europepmc +1 more source
Reassessing high-dose ranibizumab in the era of durable anti-VEGF therapy. [PDF]
Front Ophthalmol (Lausanne)Cheng CK, Tsai CJ, Bai CH.
europepmc +1 more source
A comparative study on the efficacy and safety of biosimilar (Rimmyrah) and reference ranibizumab in patients with diabetic macular edema. [PDF]
Front PharmacolZhai G, Ren X, Xu B, Mi D.
europepmc +1 more source
Cost-effectiveness analysis of the use of faricimab in diabetic macular edema in China. [PDF]
J Comp Eff ResShi F +6 more
europepmc +1 more source
Anti-vascular endothelial growth factor therapy in clinical practice: Real-world scenarios, limitations, and outcomes. [PDF]
Indian J OphthalmolSharma D, Gupta T.
europepmc +1 more source
Shaping the future of retinal care in India: Anti-VEGF therapy now and beyond. [PDF]
Indian J OphthalmolKarpe A, Narula R, Shroff D, Roy A.
europepmc +1 more source
Switching From Intravitreal Ranibizumab (Lucentis) to Biosimilar Ranibizumab (Ongavia) Injections: Insights From a Tertiary Care Eye Centre. [PDF]
CureusSourla E, Zaheer N, Chavan R.
europepmc +1 more source
COMPARE COMBINED USE OF ANTI-VEGF DRUGS DURING OR AFTER PARS PLANA VITRECTOMY FOR DIABETIC MACULAR EDEMA GUIDED BY MICROSCOPE-INTEGRATED OPTICAL COHERENCE TOMOGRAPHY. [PDF]
RetinaZhu J, Liu J, Chen YX, Yang XW, Zhu RR.
europepmc +1 more source